PAP
TVRD icon

Persistent Asset Partners’s Tvardi Therapeutics TVRD Stock Holding History

Persistent Asset Partners’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.08K Buy
+4,253
New +$13.3K ﹤0.01% 755
2025
Q4 		– Sell
-500
Closed -$19.5K – 463
2025
Q3 		$19.5K Buy
+500
New +$14.2K 0.01% 204

Other funds holding TVRD

Slate Path Capital
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Silvercrest Asset Management
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Persistent Asset Partners's TVRD Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Tvardi Therapeutics (TVRD) in Q2 2026: 4,253 shares worth $8.08K. The stake represents ﹤0.01% of the portfolio and ranks #755 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in TVRD as recently as Q3 2025.

Persistent Asset Partners first reported a position in TVRD in Q3 2025 and has held it in 2 quarters since. The position peaked at $19.5K in Q3 2025. 57 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • Persistent Asset Partners held 4,253 shares of Tvardi Therapeutics worth $8.08K as of Q2 2026.
  • Tvardi Therapeutics was a new Persistent Asset Partners position in Q2 2026.
  • Tvardi Therapeutics made up ﹤0.01% of Persistent Asset Partners's portfolio in Q2 2026, its #755 holding.
  • Persistent Asset Partners first reported a position in Tvardi Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Tvardi Therapeutics position peaked at $19.5K in Q3 2025.
  • 57 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.